‘Strikingly’ low 1-year mortality recorded for TAVR device
Findings from the PARTNER trial of the SAPIEN3 transcatheter heart valve system support the use of transcatheter aortic valve replacement as “the preferred therapy” in high-risk and inoperable patients with aortic stenosis.
Source: MedWire News - Category: Consumer Health News Tags: Interventional cardiology Source Type: news
More News: Aortic Stenosis | Cardiology | Health | Heart | Heart Valve Disease | Heart Valve Surgery | Heart Valves